

Peanut Allergy - Pipeline Review, H1 2020

<https://marketpublishers.com/r/P1A965AE4A0EN.html>

Date: April 2020

Pages: 158

Price: US\$ 2,000.00 (Single User License)

ID: P1A965AE4A0EN

Abstracts

Peanut Allergy - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H1 2020, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 6, 3, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 2 and 1 molecules, respectively.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).

The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Peanut Allergy - Overview

Peanut Allergy - Therapeutics Development

Peanut Allergy - Therapeutics Assessment

Peanut Allergy - Companies Involved in Therapeutics Development

Peanut Allergy - Drug Profiles

Peanut Allergy - Dormant Projects

Peanut Allergy - Discontinued Products

Peanut Allergy - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Peanut Allergy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Peanut Allergy - Pipeline by Adverum Biotechnologies Inc, H1 2020
Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, H1 2020
Peanut Allergy - Pipeline by Allakos Inc, H1 2020
Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H1 2020
Peanut Allergy - Pipeline by AnaptysBio Inc, H1 2020
Peanut Allergy - Pipeline by Aravax Pty Ltd, H1 2020
Peanut Allergy - Pipeline by ASIT Biotech SA, H1 2020
Peanut Allergy - Pipeline by Astellas Pharma Inc, H1 2020
Peanut Allergy - Pipeline by BioLingus AG, H1 2020
Peanut Allergy - Pipeline by BlueWillow Biologics Inc, H1 2020
Peanut Allergy - Pipeline by Cambridge Allergy Ltd, H1 2020
Peanut Allergy - Pipeline by Cour Pharmaceuticals Development Co Inc, H1 2020
Peanut Allergy - Pipeline by DBV Technologies SA, H1 2020
Peanut Allergy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Peanut Allergy - Pipeline by HAL Allergy BV, H1 2020
Peanut Allergy - Pipeline by Inimmune Corp, H1 2020
Peanut Allergy - Pipeline by InnoUp Farma SL, H1 2020
Peanut Allergy - Pipeline by Moonlight Therapeutics Inc, H1 2020
Peanut Allergy - Pipeline by ProTA Therapeutics Pty Ltd, H1 2020
Peanut Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Peanut Allergy - Pipeline by Sementis Ltd, H1 2020
Peanut Allergy - Pipeline by Vedanta Biosciences Inc, H1 2020
Peanut Allergy - Pipeline by Virtici LLC, H1 2020
Peanut Allergy - Pipeline by ZENII LLC, H1 2020

Peanut Allergy - Dormant Projects, H1 2020

Peanut Allergy - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Peanut Allergy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Adverum Biotechnologies Inc
Aimmune Therapeutics Inc
Allakos Inc
Allergy Therapeutics Plc
AnaptysBio Inc
Aravax Pty Ltd
ASIT Biotech SA
Astellas Pharma Inc
BioLingus AG
BlueWillow Biologics Inc
Cambridge Allergy Ltd
Cour Pharmaceuticals Development Co Inc
DBV Technologies SA
F. Hoffmann-La Roche Ltd
HAL Allergy BV
Inimmune Corp
InnoUp Farma SL
Moonlight Therapeutics Inc
ProTA Therapeutics Pty Ltd
Regeneron Pharmaceuticals Inc
Sementis Ltd

Vedanta Biosciences Inc
Virtici LLC
ZENII LLC

I would like to order

Product name: Peanut Allergy - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/P1A965AE4A0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P1A965AE4A0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970